Theriva Biologics
TOVX
23 hedge funds and large institutions have $31.4M invested in Theriva Biologics in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 0 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
53% more funds holding
Funds holding: 15 → 23 (+8)
35% more capital invested
Capital invested by funds: $23.3M → $31.4M (+$8.13M)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TS
Third Security
Radford,
Virginia
|
+$3.61M |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$1.96M |
| 3 |
MP
MSD Partners
New York
|
+$833K |
| 4 |
RA
Royce & Associates
New York
|
+$505K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$404K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$50.5K |
| 2 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$50.5K |
| 3 |
Morgan Stanley
New York
|
-$25.2K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
BNP Paribas Financial Markets
Paris,
France
| $1.69K | – | – | – |
|
27
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
28
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1 | – | – | – |
|
|
29
Creative Planning
Overland Park,
Kansas
| – | -$2K | – | – |
|
TOVX Hedge Fund Activity: Q4 2013 in Review
23 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2013, worth a combined $31.4M — up 35% from $23.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TOVX positions and 0 closed out — a net gain of 8 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Third Security, adding an estimated $3.61M. The largest seller was Bridgeway Capital Management, cutting an estimated $50.5K.
- 23 institutional investors held Theriva Biologics (TOVX) as of Q4 2013, up from 15 in Q3 2013.
- Funds reported $31.4M of Theriva Biologics stock for Q4 2013, up 35% quarter-over-quarter.
- 8 funds opened new Theriva Biologics positions in Q4 2013 and 0 closed out, a net change of +8 holders.
- The largest Theriva Biologics buyer in Q4 2013 was Third Security, an estimated $3.61M added.
- The largest Theriva Biologics seller in Q4 2013 was Bridgeway Capital Management, an estimated $50.5K sold.
Based on aggregated 13F filings for Q4 2013.